Prolacta Announces Major Milestone During NICU Awareness Month DUARTE, Calif. , Sept. 24, 2024 /PRNewswire/ -- Prolacta Bioscience today announced a significant milestone in premature infant nutrition.
The company's human milk-based nutritional products have been used by more than 50% of Level III and Level IV neonatal intensive care units (NICUs) in the U.S. in 2024 to care for the most vulnerable premature infants – those born weighing less than 1250 g (2.
75 lb). 1 The milestone signifies progress in neonatal care and the crucial role human milk plays in reducing complications, including the life-threatening intestinal disease, necrotizing enterocolitis (NEC). Over the past 17 years, Prolacta's 100% human milk-based nutritional products (made from donor breast milk) have become an option, over the use of cow milk-based nutrition, for premature infants in the NICU born weighing less than 1250 g.
The announcement comes during NICU Awareness Month, when professional and parent organizations are raising awareness of the nutritional standards in NICUs. Leading advocates for premature infants and their families support the adoption of human milk-based nutrition in the NICU, including: the National Black Nurses Association, Association of Women's Health, Obstetric and Neonatal Nurses, NICU Parent Network , Project NICU , and Once Upon a Preemie, Inc . "The use of Prolacta's fortifiers and formulas in NICUs across the country represents a significant advancement in neonatal care .
